NRAS and neoplasm: In our study, we observed that none of the two POLE‐positive tumors presented NRAS or BRAF mutations, but tumor T286 exhibited the p.Glu542Lys PIK3CA mutation and tumor T368 displayed the p.Lys117Asn KRAS mutation.